<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Retatrutide: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-retatrutide</link>
    <atom:link href="https://greypeptides.com/changes/retatrutide.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Retatrutide on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: What lab testing shows</title>
      <link>https://greypeptides.com/testing/#c-retatrutide</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-guide-/testing/#c-retatrutide</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.</description>
    </item>
    <item>
      <title>New guide: Retatrutide approval tracker and TRIUMPH results</title>
      <link>https://greypeptides.com/retatrutide/#tracker</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-guide-/retatrutide/#tracker</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>Every milestone dated and sourced, the phase 3 results both ways of counting, and approved alternatives at current prices.</description>
    </item>
    <item>
      <title>News: Lilly Is Suing Retatrutide Sellers: What the Company Alleges, and What Is Not Yet Known</title>
      <link>https://greypeptides.com/news/lilly-retatrutide-lawsuits-allegations/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-lilly-retatrutide-lawsuits-allegations</guid>
      <pubDate>Wed, 04 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Lilly Is Suing Retatrutide Sellers: What the Company Alleges, and What Is Not Yet Known</description>
    </item>
    <item>
      <title>News: Retatrutide Against Semaglutide in Type 2 Diabetes: What TRANSCEND-T2D-2 Shows</title>
      <link>https://greypeptides.com/news/transcend-t2d-2-retatrutide-vs-semaglutide/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-transcend-t2d-2-retatrutide-vs-semaglutide</guid>
      <pubDate>Tue, 03 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Retatrutide Against Semaglutide in Type 2 Diabetes: What TRANSCEND-T2D-2 Shows</description>
    </item>
    <item>
      <title>Correction: Corrected: Retatrutide</title>
      <link>https://greypeptides.com/corrections/#c-q970-retatrutide-triumph4</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-corr-c-q970-retatrutide-triumph4</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Correction</category>
      <description>The TRIUMPH-4 card is gone (the trial has no peer-reviewed report); the page says TRIUMPH-3 and TRIUMPH-4 have reported only topline results, attributed to Lilly's releases, and TRANSCEND-T2D-1 is carded on its Lancet report.</description>
    </item>
    <item>
      <title>News: SYNCHRONIZE-2: Survodutide Reaches 13.1% Weight Loss in Type 2 Diabetes, and 18% Stopped for Side Effects</title>
      <link>https://greypeptides.com/news/synchronize-2-survodutide-type-2-diabetes/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-synchronize-2-survodutide-type-2-diabetes</guid>
      <pubDate>Thu, 01 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>SYNCHRONIZE-2: Survodutide Reaches 13.1% Weight Loss in Type 2 Diabetes, and 18% Stopped for Side Effects</description>
    </item>
    <item>
      <title>News: The Gray Market Passed $100 Million On-Chain. Spending on Testing Fell to $8 a Buyer</title>
      <link>https://greypeptides.com/news/chainalysis-gray-market-crypto-testing-collapse/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-chainalysis-gray-market-crypto-testing-collapse</guid>
      <pubDate>Thu, 01 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>The Gray Market Passed $100 Million On-Chain. Spending on Testing Fell to $8 a Buyer</description>
    </item>
    <item>
      <title>News: Retatrutide: Lilly Plans to File in Early 2027, and Offers Single-Patient Access Before Then</title>
      <link>https://greypeptides.com/news/retatrutide-filing-2027-expanded-access/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-retatrutide-filing-2027-expanded-access</guid>
      <pubDate>Wed, 30 Sep 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Retatrutide: Lilly Plans to File in Early 2027, and Offers Single-Patient Access Before Then</description>
    </item>
    <item>
      <title>Regulatory alert: Netherlands (IGJ): The Dutch health inspectorate imposed a penalty order on the online seller it had ordered on August 24 to stop selling retatrutide, tirzepatide and semaglutide, after the seller kept selling.</title>
      <link>https://greypeptides.com/regulatory/alerts/#igj-penalty-order-online-seller</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-alert-igj-penalty-order-online-seller</guid>
      <pubDate>Mon, 31 Aug 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Dutch enforcement moved from an order to escalating penalties within a week. Retatrutide is approved nowhere, and the two approved GLP-1s are prescription medicines that a webshop may not supply.</description>
    </item>
    <item>
      <title>Regulatory alert: Netherlands (IGJ): The Dutch health inspectorate ordered an online webshop trading under several names to end the supply, delivery and trade of medicines containing retatrutide, tirzepatide and semaglutide.</title>
      <link>https://greypeptides.com/regulatory/alerts/#igj-order-online-seller</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-alert-igj-order-online-seller</guid>
      <pubDate>Mon, 24 Aug 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In the EU, selling these as 'peptides' online does not take them outside medicines law; the inspectorate treats them as medicines supplied without the required licences.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA sent warning letters to five online peptide sellers in North Carolina, Florida, Texas and Arizona, calling retatrutide, semaglutide, tirzepatide and other peptides unapproved new drugs. Posted September 1.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-five-online-sellers</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-alert-fda-wl-five-online-sellers</guid>
      <pubDate>Mon, 24 Aug 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A 'research use only' label did not decide the case: FDA read intended use from the whole website. Selling bacteriostatic water and offering a peptide calculator counted as evidence of human use.</description>
    </item>
    <item>
      <title>Regulatory alert: France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.</title>
      <link>https://greypeptides.com/regulatory/alerts/#ansm-peptides-online-warning</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-alert-ansm-peptides-online-warning</guid>
      <pubDate>Thu, 02 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional.</description>
    </item>
    <item>
      <title>Regulatory alert: Australia (Victoria): Victoria's Department of Health issued a health alert after six cases of acute liver toxicity linked to unapproved products labelled Retatrutide, Reta, R-10 or R-20.</title>
      <link>https://greypeptides.com/regulatory/alerts/#victoria-retatrutide-liver-alert</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-alert-victoria-retatrutide-liver-alert</guid>
      <pubDate>Fri, 19 Jun 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The cause may be a contaminant, so every such product is treated as at risk. Fatigue, abdominal pain, yellow skin or eyes, dark urine or easy bruising after use call for prompt medical care.</description>
    </item>
    <item>
      <title>News: TRIUMPH-1: Retatrutide Reports Up to 28.3% Weight Loss in Phase 3</title>
      <link>https://greypeptides.com/news/triumph-1-retatrutide-phase3-obesity/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-triumph-1-retatrutide-phase3-obesity</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>TRIUMPH-1: Retatrutide Reports Up to 28.3% Weight Loss in Phase 3</description>
    </item>
    <item>
      <title>News: A Single Peptide That Hits Five Receptors: The Quintuple Agonist</title>
      <link>https://greypeptides.com/news/quintuple-agonist-peptide-conjugate-nature/</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-news-quintuple-agonist-peptide-conjugate-nature</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>A Single Peptide That Hits Five Receptors: The Quintuple Agonist</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-two-online-sellers-march</link>
      <guid isPermaLink="false">greypeptides-changes-retatrutide-alert-fda-wl-two-online-sellers-march</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.</description>
    </item>
  </channel>
</rss>
